- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
56
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
56 companies
Madrigal Pharmaceuticals
Market Cap: US$12.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$529.21
7D
6.7%
1Y
74.4%
Caris Life Sciences
Market Cap: US$6.7b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$23.85
7D
-3.8%
1Y
n/a
Arcutis Biotherapeutics
Market Cap: US$3.1b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$25.00
7D
5.3%
1Y
165.1%
Marker Therapeutics
Market Cap: US$11.9m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.92
7D
-4.8%
1Y
-68.5%
Mereo BioPharma Group
Market Cap: US$283.3m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.78
7D
0.6%
1Y
-46.5%
Legend Biotech
Market Cap: US$5.6b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$30.29
7D
-4.1%
1Y
-19.1%
Lineage Cell Therapeutics
Market Cap: US$455.6m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.88
7D
3.9%
1Y
113.8%
Soleno Therapeutics
Market Cap: US$2.7b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$49.42
7D
6.7%
1Y
-4.3%
Capricor Therapeutics
Market Cap: US$256.0m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$5.60
7D
0.7%
1Y
-69.5%
ARS Pharmaceuticals
Market Cap: US$811.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$8.21
7D
-7.5%
1Y
-40.4%
Pelthos Therapeutics
Market Cap: US$103.1m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$33.61
7D
-1.1%
1Y
433.5%
Achieve Life Sciences
Market Cap: US$233.2m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.38
7D
-1.6%
1Y
5.3%
RenovoRx
Market Cap: US$27.5m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.75
7D
-24.7%
1Y
-29.9%
Aldeyra Therapeutics
Market Cap: US$303.8m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.05
7D
-1.6%
1Y
7.4%
Tenaya Therapeutics
Market Cap: US$221.5m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$1.33
7D
-7.0%
1Y
-35.4%
Longeveron
Market Cap: US$14.5m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.68
7D
-8.1%
1Y
-64.7%
AC Immune
Market Cap: US$325.5m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.29
7D
-1.8%
1Y
4.9%
Syndax Pharmaceuticals
Market Cap: US$1.4b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$16.62
7D
5.7%
1Y
3.2%
Precigen
Market Cap: US$1.7b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.85
7D
21.3%
1Y
512.2%
Viridian Therapeutics
Market Cap: US$2.7b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.77
7D
4.1%
1Y
41.4%
Sunshine Biopharma
Market Cap: US$8.0m
Operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
SBFM
US$1.63
7D
-5.2%
1Y
-28.8%
Altimmune
Market Cap: US$435.1m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$4.17
7D
-2.1%
1Y
-41.7%
NewAmsterdam Pharma
Market Cap: US$4.3b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$38.35
7D
-1.6%
1Y
55.5%
Insmed
Market Cap: US$41.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$193.22
7D
0.7%
1Y
190.1%
Invivyd
Market Cap: US$547.8m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$2.35
7D
46.0%
1Y
217.6%
Rhythm Pharmaceuticals
Market Cap: US$6.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$99.41
7D
1.8%
1Y
69.9%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.86
7D
3.7%
1Y
18.1%
Unicycive Therapeutics
Market Cap: US$100.1m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$5.67
7D
20.4%
1Y
24.6%
Rezolute
Market Cap: US$915.2m
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
RZLT
US$9.87
7D
-0.9%
1Y
102.7%
SELLAS Life Sciences Group
Market Cap: US$203.7m
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$1.43
7D
-4.7%
1Y
10.9%
BioRestorative Therapies
Market Cap: US$11.5m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.33
7D
-3.6%
1Y
-1.8%
Creative Medical Technology Holdings
Market Cap: US$8.1m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$3.15
7D
-4.0%
1Y
26.0%
Ionis Pharmaceuticals
Market Cap: US$11.6b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$71.55
7D
2.9%
1Y
112.1%
Cogent Biosciences
Market Cap: US$5.1b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$33.54
7D
3.3%
1Y
273.1%
Savara
Market Cap: US$1.0b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$4.30
7D
7.5%
1Y
45.3%
Day One Biopharmaceuticals
Market Cap: US$903.5m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$8.80
7D
-13.4%
1Y
-32.4%